DUBLIN–(BUSINESS WIRE)–The “Gouty Arthritis (Gout) – Competitive Landscape in 2021” report has been added to ResearchAndMarkets.com’s offering.
“Gouty Arthritis (Gout) – Competitive Landscape in 2021” combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Solute career transporter is a major target of drug developers. There are 51 drugs in the pipeline, 94% of which are in early-stage. Mid-sized Pharma companies dominates R&D in this indication. Rise in treatment-receiving population and increase in usage of more expensive branded therapies are expected to drive market growth.
This reports provides a data-driven overview of the current and future competitive landscape in gout therapeutics.
Scope
- Disease epidemiology
- Marketed drugs assessment
- Pipeline drugs assessment
- Clinical trials assessment
- Commercial assessment
- Social media overview
- Digital marketing overview
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global gout market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global gout in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Topics Covered:
1 Table of Contents
1.1 Preface
1.2 Abbreviations
1.3 Related Reports
1.4 Upcoming Related Reports
2 Executive Summary
2.1 Key Findings
2.2 Key Events
3 Introduction
3.1 Report Scope
3.2 Disease Overview Epidemiology Overview
3.3 Epidemiology
4 Marketed Drugs Assessment
4.1 Marketed Drugs Overview
4.2 Marketed Drug Profiles
5 Pipeline Assessment
5.1 Pipeline Overview
5.2 Pipeline Breakdown by Region
5.3 Pipeline Breakdown by Molecule Type and Target
5.4 Drug Review Designations
5.5 Phase Transition Success Rates
5.6 Likelihood of Approval
6 Clinical Trial Assessment
6.1 Clinical Trials Overview by Phase
6.2 Overview by Region
6.4 Therapy Area Perspective
6.4 Leading Sponsors
6.5 Enrollment Analytics
6.6 Feasibility Analysis
7 Commercial Assessment
7.1 Upcoming Market Catalysts
8 Social Media and Digital Marketing
8.1 Key Twitter Chatter
9 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/gt04jg
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900